|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bharadwaj M, Roy G, Dutta K, Misbah M,
Husain M and Hussain S: Tackling hepatitis B virus-associated
hepatocellular carcinoma-the future is now. Cancer Metastasis Rev.
32:229–268. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 65:1118–1127. 2011. View Article : Google Scholar
|
|
4
|
Bruix J and Llovet JM: Major achievements
in hepatocellular carcinoma. Lancet. 373:614–616. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Choi JD and Lee JS: Interplay between
epigenetics and genetics in cancer. Genomics Inform. 11:164–173.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rongrui L, Na H, Zongfang L, Fanpu J and
Shiwen J: Epigenetic mechanism involved in the HBV/HCV-related
hepatocellular carcinoma tumorigenesis. Curr Pharm Des.
20:1715–1725. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sato K, Satoh K, Tsuchida S, Hatayama I,
Shen H, Yokoyama Y, Yamada Y and Tamai K: Specific expression of
glutathione S-transferase Pi forms in (pre) neoplastic tissues:
Their properties and functions. Tohoku J Exp Med. 168:97–103. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fukushige S and Horii A: DNA methylation
in cancer: A gene silencing mechanism and the clinical potential of
its biomarkers. Tohoku J Exp Med. 229:173–185. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hessels D and Schalken JA: Urinary
biomarkers for prostate cancer: A review. Asian J Androl.
15:333–339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
White DL, Li D, Nurgalieva Z and El-Serag
HB: Genetic variants of glutathione S-transferase as possible risk
factors for hepatocellular carcinoma: A HuGE systematic review and
meta-analysis. Am J Epidemiol. 167:377–389. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoo CB and Jones PA: Epigenetic therapy of
cancer: Past, present and future. Nat Rev Drug Discov. 5:37–50.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Saito Y, Hibino S and Saito H: Alterations
of epigenetics and microRNA in hepatocellular carcinoma. Hepatol
Res. 44:31–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Borthakur G, El Ahdab SE, Ravandi F,
Faderl S, Ferrajoli A, Newman B, Issa JP and Kantarjian H: Activity
of decitabine in patients with myelodysplastic syndrome previously
treated with azacitidine. Leuk Lymphoma. 49:690–695. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Karahoca M and Momparler RL:
Pharmacokinetic and pharmacodynamic analysis of
5-aza-2′-deoxycytidine (decitabine) in the design of its
dose-schedule for cancer therapy. Clin Epigenetics. 5:32013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang J, Mao Y, Hou L and Cui X: The
effect of beta-elemene on alpha-tubulin polymerization in human
hepatoma HepG2 cells. Chin J Cancer Res. 25:7702013.PubMed/NCBI
|
|
18
|
Peng X, Zhao Y, Liang X, Wu L, Cui S, Guo
A and Wang W: Assessing the quality of RCTs on the effect of
beta-elemene, one ingredient of a Chinese herb, against malignant
tumors. Contemp Clin Trials. 27:70–82. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun Y, Liu G, Zhang Y, Zhu H, Ren Y and
Shen YM: Synthesis and in vitro anti-proliferative activity of
beta-elemene monosubstituted derivatives in HeLa cells mediated
through arrest of cell cycle at the G1 phase. Bioorg Med Chem.
17:1118–1124. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bohari SP, Hukins DW and Grover LM: Effect
of calcium alginate concentration on viability and proliferation of
encapsulated fibroblasts. Biomed Mater Eng. 21:159–170.
2011.PubMed/NCBI
|
|
21
|
Wang J, Zhang H and Sun Y: Phase III
clinical trial of elemenum emulsion in the management of malignant
pleural and peritoneal effusions. Zhonghua Zhong Liu Za Zhi.
18:464–467. 1996.(In Chinese). PubMed/NCBI
|
|
22
|
Mao Y, Zhang J, Hou L and Cui X: The
effect of beta-elemene on alpha-tubulin polymerization in human
hepatoma HepG2 cells. Chin J Cancer Res. 25:770–776.
2013.PubMed/NCBI
|
|
23
|
Lee RX, Li QQ and Reed E: β-elemene
effectively suppresses the growth and survival of both
platinum-sensitive and -resistant ovarian tumor cells. Anticancer
Res. 32:3103–3113. 2012.PubMed/NCBI
|
|
24
|
Liu JS, He SC, Zhang ZL, Chen R, Fan L,
Qiu GL, Chang S, Li L and Che XM: Anticancer effects of β-elemene
in gastric cancer cells and its potential underlying proteins: A
proteomic study. Oncol Rep. 32:2635–2647. 2014.PubMed/NCBI
|
|
25
|
Chen J, Chen YJ and Wu MD: Herbal extract
elemene intrathoracic injection in the treatment of lung cancer
patients with malignant pleural effusion: A meta-anaylsis. J Cancer
Res Ther. 10(Suppl 1): 56–59. 2014.PubMed/NCBI
|
|
26
|
Guan C, Liu W, Yue Y, Jin H, Wang X and
Wang XJ: Inhibitory effect of β-elemene on human breast cancer
cells. Int J Clin Exp Pathol. 7:3948–3956. 2014.PubMed/NCBI
|
|
27
|
Jiang ZY, Qin SK, Yin XJ, Chen YL and Zhu
L: Synergistic effects of Endostar combined with β-elemene on
malignant ascites in a mouse model. Exp Ther Med. 4:277–284.
2012.PubMed/NCBI
|
|
28
|
Shi H, Liu L, Liu L, Geng J, Zhou Y and
Chen L: β-Elemene inhibits the metastasis of B16F10 melanoma cells
by downregulation of the expression of uPA, uPAR, MMP-2 and MMP-9.
Melanoma Res. 24:99–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guo HQ, Zhang GN, Wang YJ, Zhang YK,
Sodani K, Talele TT, Ashby CR Jr and Chen ZS: β-Elemene, a compound
derived from Rhizoma zedoariae, reverses multidrug resistance
mediated by the ABCB1 transporter. Oncol Rep. 31:858–866.
2014.PubMed/NCBI
|
|
30
|
Yang H, Wang X and Yu L: The antitumor
activity of elemene is associated with apoptosis. Zhonghua Zhong
Liu Za Zhi. 18:169–172. 1996.(In Chinese). PubMed/NCBI
|
|
31
|
Zhu T, Zhao Y, Zhang J, Li L, Zou L, Yao Y
and Xu Y: β-Elemene inhibits proliferation of human glioblastoma
cells and causes cell-cycle G0/G1 arrest via mutually compensatory
activation of MKK3 and MKK6. Int J Oncol. 38:419–426.
2011.PubMed/NCBI
|
|
32
|
Dai ZJ, Tang W, Lu WF, Gao J, Kang HF, Ma
XB, Min WL, Wang XJ and Wu WY: Antiproliferative and apoptotic
effects of β-elemene on human hepatoma HepG2 cells. Cancer Cell
Int. 13:272013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang XS, Yang W, Tao SJ, Li K, Li M, Dong
JH and Wang MW: Effect of delta-elemene on Hela cell lines by
apoptosis induction. Yakugaku Zasshi. 126:979–990. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zheng CP, Tong XM, Yao HP, Yang J, Xu J,
Cai XP and Liu Z: Beta-elemene enhances aclarubicin-induced
apoptotic effect in HL-60 cells and its mechanism. Zhonghua Xue Ye
Xue Za Zhi. 30:821–824. 2009.(In Chinese). PubMed/NCBI
|
|
35
|
Zhao YS, Zhu TZ, Chen YW, Yao YQ, Wu CM,
Wei ZQ, Wang W and Xu YH: B-elemene inhibits Hsp90/Raf-1 molecular
complex inducing apoptosis of glioblastoma cells. J Neurooncol.
107:307–314. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yao CC, Tu YR, Jiang J, Ye SF, Du HX and
Zhang Y: β-elemene reverses the drug resistance of lung cancer
A549/DDP cells via the mitochondrial apoptosis pathway. Oncol Rep.
31:2131–2138. 2014.PubMed/NCBI
|
|
37
|
Rezaei MK, Shobbar ZS, Shahbazi M, Abedini
R and Zare S: Glutathione S-transferase (GST) family in barley:
identification of members, enzyme activity, and gene expression
pattern. J Plant Physiol. 170:1277–1284. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tchou JC, Lin X, Freije D, Isaacs WB,
Brooks JD, Rashid A, De Marzo AM, Kanai Y, Hirohashi S and Nelson
WG: GSTP1 CpG island DNA hypermethylation in hepatocellular
carcinomas. Int J Oncol. 16:663–676. 2000.PubMed/NCBI
|
